Dan

BASEL, Switzerland, May 9, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of its Management Team will present at BioEquity Europe taking place May 14-16, 2023, in Dublin, Ireland. Noema management will provide an update on its clinical development activities and outline anticipated […]

BASEL, Switzerland and BOSTON, Massachusetts, January 5, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA. Presentation DetailsDate: Tuesday 10

BASEL, Switzerland, October 18, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN). Fast Track designation aims at facilitating the development

Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgia LIBRATN (NOE-101 Phase 2/3 study in Trigeminal Neuralgia) is on track to report top-line data in H1 2024 BASEL, Switzerland/ Boston, MA, September 6, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating

Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, Switzerland / Boston, MA, June 27, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces the US Food and Drug Administration (FDA)